Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC

被引：0

作者：

Griesingerl, Frank ^{[1
]}

Garassino, Marina ^{[2
,3
]}

Felip, Enriqueta ^{[4
]}

Sakai, Hiroshi ^{[5
,6
]}

Le, Xiuning ^{[7
]}

Veillon, Remi ^{[8
]}

Smit, Egbert ^{[9
]}

Raskin, Jo ^{[10
]}

Thomas, Michael ^{[11
,12
,13
]}

Ahn, Myung-Ju ^{[14
]}

Lee, Matthew ^{[15
]}

Vlassak, Soetkin ^{[16
,17
]}

Bruns, Rolf ^{[18
]}

Johne, Andreas ^{[19
]}

Palle, Paul K. ^{[20
]}

机构：

[1] Carl von Ossietzky Univ Oldenburg, Dept Hematol & Oncol, Pius Hosp, Oldenburg, Germany

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] Univ Chicago, Hematol Oncol Sect, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA

[4] Vali Hebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain

[5] Saitama Canc Ctr, Dept Thorac Oncol, Saitama, Japan

[6] Ageo Cent Gen Hosp, Dept Thorac Oncol, Saitama, Japan

[7] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA

[8] CHU Bordeaux, Serv Malad Resp, Bordeaux, France

[9] Leiden Univ, Dept Pulm Dis, Med Ctr, Leiden, Netherlands

[10] Antwerp Univ Hosp UZA, Dept Pulmonol & Thorac Oncol, Edegem, Belgium

[11] Univ Heidelberg Hosp, Thoraxklin & Natl Ctr Tumor Dis, Heidelberg, Germany

[12] Translat Lung Res Ctr Heidelberg TLRCH, Heidelberg, Germany

[13] German Ctr Lung Res DZL, Heidelberg, Germany

[14] Sungkyunkwan Univ, Hematol Oncol Sect, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[15] EMD Serono, Rockland, MA USA

[16] Merck NS SA, Global Med Affairs, Overijse, Belgium

[17] Merck KGaA, Darmstadt, Germany

[18] Healthcare Business Merck KGaA, Dept Biostat, Darmstadt, Germany

[19] Healthcare Business Merck KGaA, Global Clin Dev, Darmstadt, Germany

[20] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PP01.83

引用

页码：E37 / E38

页数：2

共 50 条

[21] Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
Paik, P.
Sakai, H.
Felip, E.
Veillon, R.
Garassino, M. C.
Raskin, J.
Viteri, S.
Mazieres, J.
Cortot, A.
Smit, E.
Thomas, M.
Cho, B. C.
Conte, P.
Yang, J. C.
Morise, M.
Chen, Y.
Park, K.
Gottfried, M.
Britschgi, C.
Bruns, R.
Otto, G.
Johne, A.
Le, X.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S174 - S174
[22] Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A
Mazieres, J.
Paik, P. K.
Felip, E.
Veillon, R.
Sakai, H.
Cortot, A. B.
Viteri, S.
Garassino, M. C.
Van Meerbeeck, J. P.
Raskin, J.
Thomas, M.
Morise, M.
Cho, B. C.
Conte, P.
Bruns, R.
Demuth, T.
Schumacher, K. M.
Le, X.
ANNALS OF ONCOLOGY, 2020, 31 : S828 - S829
[23] Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
Felip, E.
Garassino, M. C.
Sakai, H.
Le, X.
Veillon, R.
Smit, E.
Mazieres, J.
Cortot, A.
Raskin, J.
Thomas, M.
Viteri, S.
Iams, W.
Kim, H. R.
Yang, J.
Stroh, C.
Otto, G.
Bruns, R.
Paik, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1085 - S1086
[24] Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION Cohort A
Thomas, M.
Reinmuth, N.
Wermke, M.
Griesinger, F.
Overbeck, T.
Alt, J.
Henschke, S.
Wehler, T.
Ochsenreither, S.
Garassino, M. C.
Felip, E.
Sakai, H.
Bruns, R.
Otto, G.
Johne, A.
Paik, P. K.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 108 - 109
[25] Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
Garassino, M. C. C.
Felip, E.
Sakai, H.
Le, X.
Veillon, R.
Smit, E. F. F.
Mazieres, J.
Cortot, A. B.
Raskin, J.
Thomas, M.
Viteri, S.
Iams, W. T.
Kim, H. R.
Yang, J.
Berghoff, K.
Bruns, R.
Otto, G.
Paik, P. K.
ANNALS OF ONCOLOGY, 2021, 32 : S984 - S985
[26] Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL).
Paik, Paul K.
Horn, Leora
Kowalski, Dariusz M.
Patel, Jyoti D.
Griesinger, Frank
Han, Ji-Youn
Smit, Egbert F.
Kato, Terufumi
Le, Xiuning
Scheele, Jurgen
Bruns, Rolf
Vioix, Helene
Pfeiffer, Boris M.
Cho, Byoung Chul
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27] Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study
Park, K.
Felip, E.
Veillon, R.
Cortot, A.
Mazieres, J.
Sakai, H.
Reinmuth, N.
Viteri, S.
Chen, Y-M.
Han, J-Y.
Jang, T-W.
Morise, M.
Sakamoto, T.
Tokito, T.
Cho, B. C.
Bruns, R.
Scheele, J.
Straub, J.
Le, X.
Paik, P. K.
ANNALS OF ONCOLOGY, 2019, 30
[28] Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC
Mazieres, J.
Veillon, R.
Felip, E.
Le, X.
Garassino, M. C.
Stanton, T.
Morise, M.
Lee, J.
Matsumoto, S.
De Marinis, F.
Wehler, T.
Clark, A.
Friese-Hamin, M.
Stroh, C.
Bruns, R.
Otto, G.
Paik, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S668 - S669
[29] Health-Related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib
Garassino, M.
Le, X.
Kowalski, D.
Migliorino, M.
Senellert, H.
Pradera, J.
Walling, R.
Kato, T.
Thomas, M.
Smit, E.
Gottfried, M.
Britschgi, C.
Johne, A.
Scheele, J.
Bruns, R.
Vioix, H.
Pfeiffer, B.
Paik, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S35 - S35
[30] ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial
Le, Xiuning
Garassino, Marina Chiara
Ahn, Myung-Ju
Felip, Enriqueta
Cortot, Alexis B.
Sakai, Hiroshi
Mazieres, Julien
Thomas, Michael
Viteri, Santiago
Conte, Pierfranco
Yang, James Chih-Hsin
Lams, Wade Thomas
Griesinger, Frank
O'Hara, Richard M., Jr.
Stroh, Christopher
Juraeva, Dilafruz
Wang, Danyi
Johne, Andreas
Paik, Paul K.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E4 - E4

← 1 2 3 4 5 →